• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chrysalis BioTherapeutics receives $1.5m from the National Cancer Institute

Chrysalis BioTherapeutics receives $1.5m from the National Cancer Institute

September 25, 2013
CenterWatch Staff

Chrysalis BioTherapeutics has announced receipt of a $1.5 million contract from the National Cancer Institute (NCI) to continue its development of Chrysalin to mitigate radiotherapy-induced damage to normal brain tissue.

Radiotherapy is a primary tool for controlling tumor growth, yet damage to surrounding normal tissues limit the amount of radiation that can be used to kill tumors. Moreover, side-effects of radiotherapy can have long lasting effects on patients, especially in the brain where radiation can affect learning, memory and physical functions.

According to SEER Cancer Statics, nearly one in 161 people will be diagnosed with brain or nervous system cancer during their lifetime. Finding ways to mitigate damage from radiotherapy or restore neural function following radiotherapy may allow more effective cancer treatment to increase survival and improve quality-of-life for survivors.

This project is a collaboration between Chrysalis BioTherapeutics, Baylor College of Medicine (BCM) and the University of Texas Medical Branch (UTMB). Preclinical results indicate Chrysalin treatment restores radiation-damaged neural integrity and promotes neurogenesis in the hippocampus.

Chrysalin is a naturally occurring regenerative peptide being developed by Chrysalis BioTherapeutics under worldwide license from UTMB to mitigate effects of nuclear radiation and radiotherapy. 

"These effects of Chrysalin may be very important," said Dr. Mostafa Waleed Gaber, associate professor at Baylor College of Medicine and co-director of the Small Animal Imaging Facility at Texas Children's Hospital, "especially in children where successful radiotherapy treatment of brain tumors may have life-long effects on cognitive function."

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing